secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0001654954-23-007426
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics receives USPTO Notice of Allowance for oral levosimendan patent in PH-HFpEF
--------------------------------------------------------------------------------

- Patent covers oral levosimendan (TNX-103) for PH-HFpEF; term through Dec 2040, possible extension beyond.
- No FDA-approved treatments exist for PH-HFpEF, affecting >1.6M North Americans, projected >2M by 2030.
- Phase 2 HELP study showed levosimendan improved 6-minute walk by 29 meters (p=0.03) vs placebo.
- Tenax intends to initiate Phase 3 trial of oral formulation in 2023; FDA agreed 6-minute walk test as primary endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495423007426/0001654954-23-007426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495423007426/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-007426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer